AR030737A1 - Metodo de anticoncepcion y forma de administracion del mismo - Google Patents
Metodo de anticoncepcion y forma de administracion del mismoInfo
- Publication number
- AR030737A1 AR030737A1 ARP010104361A ARP010104361A AR030737A1 AR 030737 A1 AR030737 A1 AR 030737A1 AR P010104361 A ARP010104361 A AR P010104361A AR P010104361 A ARP010104361 A AR P010104361A AR 030737 A1 AR030737 A1 AR 030737A1
- Authority
- AR
- Argentina
- Prior art keywords
- intake
- administration
- duration
- intakes
- period
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Un método para la anticoncepcion hormonal, que consta de una pluralidad de períodos de ingesta ligados entre sí, sustancialmente ilimitados en el tiempo, y que optativamente presentan una secuencia que se extiende por varios anos y que en cada caso comprende por lo menos un ciclo de ingesta, con una fase de ingesta de duracion constante que dura varios días dentro de dicho período de ingesta particular, y una pausa entre ingestas que dura varios días. En la o las fases de ingesta, la administracion diaria consiste de una unidad diaria que contiene por lo menos un componente hormonal de accion anticonceptiva, tal como un estrogeno y/o gestágeno. En la o las pausas entre ingestas, la administracion consiste ya sea de placebos libres de todo componente hormonal o bien, la pausa entre ingestas particular permanece completamente libre de administracion alguna. La duracion de la o las fases de ingesta de por lo menos el ultimo período de ingesta dura por lo menos 22 días. La o las fases de ingesta están caracterizadas porque la duracion de las mismas en cualquier período de ingesta que precede a un siguiente período de ingesta es menor que la duracion, en cada caso, de dicho período de ingesta siguiente. También se describe una forma de administracion para una anticoncepcion hormonal y, en particular, para aplicar dicho método.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10045380A DE10045380A1 (de) | 2000-09-14 | 2000-09-14 | Verfahren zur Kontrazeption und dessen Darreichungsform |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR030737A1 true AR030737A1 (es) | 2003-09-03 |
Family
ID=7656125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010104361A AR030737A1 (es) | 2000-09-14 | 2001-09-14 | Metodo de anticoncepcion y forma de administracion del mismo |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US8076317B2 (es) |
| EP (2) | EP2153849A3 (es) |
| JP (3) | JP2004508398A (es) |
| KR (3) | KR20090033502A (es) |
| CN (1) | CN100560132C (es) |
| AR (1) | AR030737A1 (es) |
| AT (1) | ATE447972T1 (es) |
| AU (2) | AU2001284052B2 (es) |
| BG (2) | BG107625A (es) |
| BR (1) | BR0113902A (es) |
| CA (1) | CA2420292C (es) |
| CZ (1) | CZ2003723A3 (es) |
| DE (2) | DE10045380A1 (es) |
| EA (1) | EA006875B1 (es) |
| EE (1) | EE200300103A (es) |
| HR (1) | HRP20030294A2 (es) |
| HU (1) | HUP0301042A3 (es) |
| IL (2) | IL154521A0 (es) |
| ME (1) | ME00291B (es) |
| MX (1) | MXPA03002070A (es) |
| NO (1) | NO20031152L (es) |
| NZ (1) | NZ524448A (es) |
| PE (1) | PE20020425A1 (es) |
| PL (1) | PL361161A1 (es) |
| SK (1) | SK3102003A3 (es) |
| TW (1) | TWI297271B (es) |
| UA (1) | UA93650C2 (es) |
| UY (1) | UY26932A1 (es) |
| WO (1) | WO2002022110A2 (es) |
| YU (1) | YU19003A (es) |
| ZA (1) | ZA200301359B (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004019743B4 (de) | 2004-04-20 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens |
| AU2011226911B2 (en) * | 2004-04-30 | 2014-06-19 | Bayer Intellectual Property Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
| MY151322A (en) * | 2004-04-30 | 2014-05-15 | Bayer Ip Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
| DE102004026670A1 (de) * | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat |
| DE102004026679A1 (de) * | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat |
| DE102004026671A1 (de) | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Darreichungsform zur hormonalen Kontrazeption |
| DE102004026669A1 (de) * | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels |
| EP1655031A1 (de) | 2004-10-08 | 2006-05-10 | Schering AG | Dienogest enthaltendes Langzeit-Verfahren zur Empfängnisverhütung |
| TW200727920A (en) * | 2005-06-21 | 2007-08-01 | Organon Nv | New regimens for oral monophasic contraceptives |
| TW200744610A (en) * | 2005-06-21 | 2007-12-16 | Organon Nv | New regimens for controlled drug delivery devices for contraception |
| US8153616B2 (en) | 2005-10-17 | 2012-04-10 | Bayer Pharma Aktiengesellschaft | Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same |
| DE102006003509A1 (de) * | 2006-01-24 | 2007-07-26 | Grünenthal GmbH | Kontrazeptivum |
| EP1930010A1 (de) | 2006-10-20 | 2008-06-11 | Bayer Schering Pharma Aktiengesellschaft | Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido |
| GB0623813D0 (en) * | 2006-11-29 | 2007-01-10 | Stephenson Group Ltd | Foam reduction |
| DE102007011486A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Arzneimittel umfassend wenigstens ein Gestagen |
| EP2140860A1 (en) * | 2008-07-03 | 2010-01-06 | Bayer Schering Pharma Oy | An improved method of contraception |
| BR112014012444B1 (pt) | 2011-11-23 | 2021-12-14 | Therapeuticsmd, Inc | Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| CA2947767A1 (en) | 2014-05-22 | 2015-11-26 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2365103C3 (de) * | 1973-12-21 | 1980-08-28 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | V erwendung von Hormonen zur Kontrazeption |
| NL9301562A (nl) * | 1993-09-09 | 1995-04-03 | Saturnus Ag | Preparaat voor substitutietherapie. |
| DE4344462C2 (de) * | 1993-12-22 | 1996-02-01 | Schering Ag | Zusammensetzung für die Empfängnisverhütung |
| DE69532894T2 (de) * | 1994-11-22 | 2004-09-02 | Balance Pharmaceuticals, Inc., Pacific Palisades | Verfahren zur empfängnisverhütung |
| DE19525017A1 (de) * | 1995-06-28 | 1997-01-02 | Schering Ag | Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption |
| US5922349A (en) * | 1995-09-28 | 1999-07-13 | Schering Aktiengesellschaft | Hormone replacement therapy method and hormone dispenser |
| NZ333750A (en) | 1996-07-26 | 2000-09-29 | American Home Prod | Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen |
| US5898032A (en) * | 1997-06-23 | 1999-04-27 | Medical College Of Hampton Roads | Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy |
-
2000
- 2000-09-14 DE DE10045380A patent/DE10045380A1/de not_active Withdrawn
-
2001
- 2001-09-05 BR BR0113902-9A patent/BR0113902A/pt active Search and Examination
- 2001-09-05 NZ NZ524448A patent/NZ524448A/en not_active IP Right Cessation
- 2001-09-05 PL PL36116101A patent/PL361161A1/xx not_active Application Discontinuation
- 2001-09-05 JP JP2002526362A patent/JP2004508398A/ja not_active Withdrawn
- 2001-09-05 SK SK310-2003A patent/SK3102003A3/sk not_active Application Discontinuation
- 2001-09-05 DE DE60140462T patent/DE60140462D1/de not_active Expired - Lifetime
- 2001-09-05 EA EA200300338A patent/EA006875B1/ru not_active IP Right Cessation
- 2001-09-05 UA UA2003043067A patent/UA93650C2/ru unknown
- 2001-09-05 WO PCT/EP2001/010207 patent/WO2002022110A2/en not_active Ceased
- 2001-09-05 HR HR20030294A patent/HRP20030294A2/hr not_active Application Discontinuation
- 2001-09-05 CN CNB018155707A patent/CN100560132C/zh not_active Expired - Fee Related
- 2001-09-05 CZ CZ2003723A patent/CZ2003723A3/cs unknown
- 2001-09-05 EE EEP200300103A patent/EE200300103A/xx unknown
- 2001-09-05 KR KR1020097005863A patent/KR20090033502A/ko not_active Withdrawn
- 2001-09-05 US US10/380,405 patent/US8076317B2/en not_active Expired - Fee Related
- 2001-09-05 AT AT01962996T patent/ATE447972T1/de not_active IP Right Cessation
- 2001-09-05 ME MEP-2008-376A patent/ME00291B/me unknown
- 2001-09-05 HU HU0301042A patent/HUP0301042A3/hu unknown
- 2001-09-05 EP EP09014071A patent/EP2153849A3/en not_active Ceased
- 2001-09-05 IL IL15452101A patent/IL154521A0/xx unknown
- 2001-09-05 EP EP01962996A patent/EP1317286B1/en not_active Expired - Lifetime
- 2001-09-05 CA CA2420292A patent/CA2420292C/en not_active Expired - Fee Related
- 2001-09-05 KR KR10-2003-7003667A patent/KR20030031185A/ko not_active Ceased
- 2001-09-05 YU YU19003A patent/YU19003A/sh unknown
- 2001-09-05 KR KR1020107010166A patent/KR101240232B1/ko not_active Expired - Fee Related
- 2001-09-05 MX MXPA03002070A patent/MXPA03002070A/es active IP Right Grant
- 2001-09-05 AU AU2001284052A patent/AU2001284052B2/en not_active Ceased
- 2001-09-05 AU AU8405201A patent/AU8405201A/xx active Pending
- 2001-09-10 PE PE2001000903A patent/PE20020425A1/es not_active Application Discontinuation
- 2001-09-11 UY UY26932A patent/UY26932A1/es not_active Application Discontinuation
- 2001-09-12 TW TW090122607A patent/TWI297271B/zh not_active IP Right Cessation
- 2001-09-14 AR ARP010104361A patent/AR030737A1/es not_active Application Discontinuation
-
2003
- 2003-02-18 IL IL154521A patent/IL154521A/en not_active IP Right Cessation
- 2003-02-19 ZA ZA200301359A patent/ZA200301359B/en unknown
- 2003-03-11 BG BG107625A patent/BG107625A/bg unknown
- 2003-03-13 NO NO20031152A patent/NO20031152L/no not_active Application Discontinuation
-
2011
- 2011-11-18 BG BG10111090A patent/BG111090A/bg unknown
- 2011-12-12 US US13/316,887 patent/US8536156B2/en not_active Expired - Fee Related
-
2012
- 2012-09-10 JP JP2012198547A patent/JP2013006866A/ja not_active Withdrawn
-
2013
- 2013-08-09 JP JP2013166891A patent/JP2013241456A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR030737A1 (es) | Metodo de anticoncepcion y forma de administracion del mismo | |
| KR960706344A (ko) | 호르몬 피임 및/또는 여드름 치료 수단 및 방법(means and method for hormonal contraception and/or the treatment of acne) | |
| ES2190472T3 (es) | Parche transdermico para la administracion de 17-deacetil norgestimato, solo o en combinacion con un estrogeno. | |
| ES2087964T3 (es) | Contraceptivos orales bajos en estrogenos. | |
| PA8638601A1 (es) | Regimenes y kits de progestina ciclica | |
| AR005703A1 (es) | Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen | |
| EA200201000A1 (ru) | Гормон-заместительная терапия | |
| DE60131850D1 (de) | Hautpflegezusammensetzungen, die silikonelastomere enthalten | |
| Unny et al. | A review on potentiality of medicinal plants as the source of new contraceptive principles | |
| SV2002000231A (es) | Compuestos 2,4,-diaminopirimidina utiles como inmunosupresores ref. pc10547/20083/bb | |
| NO986104L (no) | Progesteron-anti-progesteron regimer | |
| EA201200377A1 (ru) | Способ пероральной контрацепции у женщин, способ управления нежелательными кровотечениями и предназначенная для применения в этих способах фармацевтическая упаковка | |
| UY24308A1 (es) | Tabletas exentas de aglutinante que contienen tramadol o una sal de tramadol, para administracion oral | |
| FI964285A0 (fi) | Taksaanien luokkaan kuuluviin johdannaisiin perustuvat farmaseuttiset valmisteet | |
| NO20024646D0 (no) | Kombinasjonsterapier med vaskul¶r-skadende aktivitet | |
| BRPI0407652A (pt) | método para acentuar a eficácia de um agente ativo, composição e método para produzir a composição | |
| ES2165232T3 (es) | Sistema terapeutico transdermico (tts) que contiene oxibutinina. | |
| BRPI0509053A (pt) | composição farmacêutica anidra e uso de um agente siliconado e de uma composição | |
| AR043918A1 (es) | Reduccion del crecimiento del vello utilizando una composicion que contiene difluorometilornitina | |
| KR970061246A (ko) | 테스토스테론을 증가시키기 위한 약학 조성물 | |
| ATE237331T1 (de) | Deuterierte wirkstoffe in transdermaler applikation | |
| AR036321A1 (es) | Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia. | |
| NO20072893L (no) | Fast, peroralt prevensjonsmiddel | |
| CO5690602A2 (es) | Regimenes anticonceptivos trifasicos extendidos | |
| PE20011121A1 (es) | Composicion farmaceutica que comprende un compuesto ciclico con un grupo sulfamato |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |